Valuation: CombiGene AB

Market Cap 4.34Cr 45.43L 39.45L 36.78L 33.79L 63.9L 43Cr 64.61L 1.7Cr 22Cr 1.71Cr 1.67Cr 72Cr P/E 2024
-1.05x
P/E 2025 -3.62x
Enterprise Value 3.75Cr 39.31L 34.14L 31.83L 29.24L 55.3L 37Cr 55.9L 1.47Cr 19Cr 1.48Cr 1.44Cr 62Cr EV / Sales 2024
-13.3x
EV / Sales 2025 128x
Free-Float
44.24%
Yield 2024
8.4%
Yield 2025 88.5%
1 day+0.92%
1 week-3.10%
Current month-1.35%
1 month-2.23%
3 months-5.19%
6 months+1.86%
Current year-3.10%
1 week 2.16
Extreme 2.16
2.28
1 month 2.16
Extreme 2.16
2.38
Current year 1.75
Extreme 1.75
2.6
1 year 1.75
Extreme 1.75
2.87
3 years 1.27
Extreme 1.27
7.4
5 years 1.27
Extreme 1.27
20.05
10 years 1.27
Extreme 1.27
147
Manager TitleAgeSince
Chief Executive Officer 48 31/07/2025
Director TitleAgeSince
Director/Board Member 54 10/12/2024
Chairman - 01/01/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%-3.10%-5.60%-65.78% 45.43L
+10.00%+14.90%+53.89%+87.07% 6.25TCr
+0.80%-5.70%+23.89%+62.65% 5.24TCr
-0.98%-1.19%-16.98%-14.21% 2.31TCr
+0.30%-5.17%-11.23%+349.07% 2.14TCr
+1.73%-1.57%+32.81%-25.80% 1.78TCr
+4.29%+8.97%+200.03%+341.85% 1.55TCr
+2.08%-0.92%+13.86%+614.49% 1.47TCr
+1.71%-0.90%+52.13%+176.27% 1.41TCr
+4.16%+4.44%+444.12%+183.06% 1.26TCr
Average +2.53%+0.58%+78.69%+170.87% 2.34TCr
Weighted average by Cap. +3.67%+1.83%+60.70%+147.45%

Financials

2024 2025
Net sales 19.99L 2L 2L 2L 2L 3L 1.99Cr 3L 8L 99.6L 8L 8L 3.3Cr 3L 31.85T 27.66T 25.79T 23.69T 44.8T 30.3L 45.29T 1L 15.14L 1L 1L 50.18L
Net income -4.49Cr -47.02L -40.83L -38.07L -34.97L -66.13L -45Cr -66.86L -1.75Cr -22Cr -1.77Cr -1.73Cr -74Cr -1.24Cr -12.95L -11.24L -10.48L -10L -18.21L -12Cr -18.41L -48.31L -6.16Cr -48.63L -47.56L -20Cr
Net Debt -7.37Cr -77.27L -67.09L -62.55L -57.46L -1.09Cr -73Cr -1.1Cr -2.88Cr -37Cr -2.9Cr -2.84Cr -121.74Cr -58.42L -6L -5L -5L -5L -9L -5.82Cr -9L -22.84L -2.91Cr -22.99L -22.48L -9.64Cr
Logo CombiGene AB
Larkberget AB, formerly Combigene AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Employees
5
Date Price Change Volume
04/26/04 SEK 2.190 +0.92% 24,735
03/26/03 SEK 2.170 -2.25% 1,796
31/26/31 SEK 2.220 -0.89% 2,031
30/26/30 SEK 2.240 0.00% 143
29/26/29 SEK 2.240 -0.88% 4,785
  1. Stock Market
  2. Stocks
  3. LARK Stock